midkine inhibitors (Cellmid/Universidad Complutense)

N/A

Report date: 2025/06/11 10:34:25

Base Information

Drug Namemidkine inhibitors (Cellmid/Universidad Complutense)
Drug Alias Namebrain cancer therapy (cellmid/Universidad Complutense de Madrid)midkine inhibitors (Lyramid/Universidad Complutense)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionMidkine inhibitors
TargetsMidkine
Therapy Area/IndicationsInflammationAutoimmune DiseasesBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandSpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnagenics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRoquefort Therapeutics plc
Inactive CompaniesLyramid LtdAnagenics LtdLa Universidad Complutense de Madrid
Active IndicationsInflammationAutoimmune DiseasesBrain Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A